Androgen therapy for loss of desire in women: is the benefit worth the breast cancer risk?

Fertility and Sterility

Volumn 90, Issue 1, 2008, Pages 129-140

  Schover, Leslie R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

androgens; breast cancer; hormonal therapy; hypoactive sexual desire disorder; Testosterone

Indexed keywords

ANDROGEN; ESTROGEN; PROGESTERONE DERIVATIVE; TESTOSTERONE; TIBOLONE;

AGING; ANDROGEN THERAPY; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; EMOTIONAL STRESS; FITNESS; HUMAN; LIFE STRESS; MEDICAL LITERATURE; MEDICAL RESEARCH; MENOPAUSAL SYNDROME; OBESITY; OVARIECTOMY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUAL SATISFACTION; TREATMENT OUTCOME;

ADULT; AGED; ANDROGENS; BREAST NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; LIBIDO; MIDDLE AGED; OBESITY; PATIENT SELECTION; PHYSICAL FITNESS; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; TESTOSTERONE; TREATMENT OUTCOME;

EID: 45849111454     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.05.057     Document Type: Article

References (90)

1. Laumann E.O., Paik A., and Rosen R.D. Sexual dysfunction in the United States: prevalence and predictors. JAMA 281 (1999) 537-544
2. Avis N.E., Zhao X., Johannes C.B., Ory M., Brockwell S., and Greendale G.A. Correlates of sexual function among multi-ethnic middle-aged women: results from the Study of Women's Health Across the Nation (SWAN). Menopause 2 (2005) 385-398
3. Gracia C.R., Freeman E.W., Sammel M.D., Lin H., and Mogul M. Hormones and sexuality during transition to menopause. Obstet Gynecol 109 (2007) 831-840
4. Moreira E.D., Brock G., Glasser D.B., Nicolosi A., Laumann E.O., Paik A., et al., Global Study of Sexual Attitudes and Behaviors Study Group. Help-seeking behaviour for sexual problems: the Global Study of Sexual Attitudes and Behaviors. Int J Clin Pract 59 (2005) 6-16
5. Spark R.F. Intrinsa fails to impress FDA advisory panel. Int J Impot Res 17 (2005) 283-284
6. Wierman M.E., Basson R., Davis S.R., Khosla S., Miller K.K., Rosner W., and Santoro N. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91 (2006) 3697-3710
7. ®. EPAR Summary for the Public. EMEA/H/C/634, June 2006. Available at: http://www.emea.eu.int/humandocs/PDFs/EPAR/intrinsa/063406en1.pdf. Accessed May 2, 2007.
8. BioSante Pharmaceuticals Investor Fact Sheet, January 2007. Available at: http://www.biosantepharma.com/pub/factsheet.pdf. Accessed May 15, 2007.
9. Vivus, Inc. Testosterone metered dose transdermal spray (MDTR®)-for treatment of low sexual desire in women. Available at: http://www.vivus.com/main.taf?p=3,3,3,2. Accessed May 15, 2007.
10. Advisory Committee Briefing Document. Intrinsa® (testosterone transdermal system), NDA No. 21-769. Procter& Gamble Pharmaceuticals, Inc. Advisory Committee for Reproductive Health Drugs, December 02, 2004, p. 15 Available at: http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4082B1_01_A-P%26G-I ntrinsa.pdf. Accessed June 15, 2007.
11. Freeman M.P. Testosterone supplementation in women: prescribing practices in one community. J Womens Health 13 (2004) 239-240
12. Kornblut AE, Wilson D. How one pill escaped place on steroid list. New York Times, April 17, 2005. Available at: http://www.biopsychiatry.com/dhea/legal.html. Accessed May 2, 2007.
13. Labrie F., Luu-The V., Martel C., Chernomoretz A., Calvo E., Morissette J., et al. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol 100 (2006) 52-58
14. Labrie F., Belanger A., Belanger P., Bérubé R., Martel C., Cusan L., et al. Metabolism of DHEA in postmenopausal women following percutaneous administration. J Steroid Biochem Mol Biol 103 (2007) 178-188
15. Schonberg M.A., Davis R.B., and Wee C.C. After the Women's Health Initiative: decision making and trust of women taking hormone therapy. Womens Health Issues 15 (2005) 187-195
16. Basson R. Rethinking low sexual desire in women. BJOG 109 (2002) 357-363
17. Basson R., Leiblum S., Brotto L., Derogatis L., Fourcroy J., Fugl-Meyer K., et al. Revised definitions of women's sexual dysfunction. J Sex Med 1 (2004) 40-48
18. Hayes R.D., Dennerstein L., Bennett C.M., Koochaki P.E., Leiblum S.R., and Graziottin A. Relationship between hypoactive sexual desire disorder and aging. Fertil Steril 87 (2007) 107-112
19. Sands R., and Studd J. Exogenous androgens in postmenopausal women. Am J Med 98 (1995) 76S-79S
20. Bachmann G., Bancroft J., Braunstein G., Burger H., Davis S., Dennerstein L., et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril 77 (2002) 660-665
21. Rivera-Woll L.M., Papalia M., Davis S.R., and Burger H.G. Androgen insufficiency in women: diagnostic and therapeutic implications. Hum Reprod Update 10 (2004) 421-432
22. Cawood E.H., and Bancroft J. Steroid hormones, the menopause, sexuality and well-being of women. Psychol Med 26 (1996) 925-936
23. Gracia C.R., Sammel M.D., Freeman E.W., Liu L., Hollander L., and Nelson D.B. Predictors of decreased libido in women during the late reproductive years. Menopause 1 (2004) 144-150
24. Dennerstein L., Randolph J., Taffe J., Dudley E., and Burger H. Hormones, mood, sexuality, and the menopausal transition. Fertil Steril 77 Suppl 4 (2002) S42-S48
25. Dennerstein L., Lehert P., and Burger H. The relative effects of hormones and relationship factors on sexual function of women though the natural menopausal transition. Fertil Steril 84 (2005) 174-180
26. Davis S.R., Davison S.L., Donath S., and Bell R.J. Circulating androgen levels and self-reported sexual function in women. JAMA 294 (2005) 91-96
27. Santoro N., Torrens J., Crawford S., Allsworth J.E., Finkelstein J.S., Gold E.B., et al. Correlates of circulating androgens in mid-life women: the Study of Women's Health Across the Nation. J Clin Endocrin Metab 90 (2005) 4836-4845
28. Mishra G., and Kuh D. Sexual functioning throughout menopause: the perceptions of women in a British cohort. Menopause 13 (2006) 880-890
29. Modelska K., Litwack S., Ewing S.K., and Yaffe K. Endogenous estrogen levels affect sexual function in elderly post-menopausal women. Maturitas 49 (2004) 124-133
30. Dennerstein L., Koochaki P., Barton I., and Graziottin A. Hypoactive sexual desire disorder in menopausal women: a survey of western European women. J Sex Med 3 (2006) 212-222
31. Leiblum S.R., Koochaki P.E., Rodenberg C.A., Barton I.P., and Rosen R.C. Hypoactive sexual desire disorder in postmenopausal women: US results from the Women's International Study of Health and Sexuality (WISHeS). Menopause 13 (2006) 46-56
32. Aziz A., Brännstrom M., Bergquist C., and Silfverstolpe G. Perimenopausal androgen decline after oophorectomy does not influence sexuality or psychological well-being. Fertil Steril 83 (2005) 1021-1028
33. Aziz A., Bergquist C., Brännstrom M., Nordholm L., and Silfverstolpe G. Differences in aspects of personality and sexuality between perimenopausal women making different choices regarding prophylactic oophorectomy at elective hysterectomy. Act Obstet Gynecol Scand 85 (2005) 854-859
34. Farquhar C.M., Harvey S.A., Yu Y., Sadler L., and Stewart A.W. A prospective study of 3 years of outcomes after hysterectomy with and without oophorectomy. Am J Obstet Gynecol 194 (2006) 711-717
35. McKinlay J.B., McKinlay S.M., and Brambilla D.J. Health status and utilization behavior associated with menopause. Am J Epidemiol 125 (1987) 110-121
36. Shifren J.L., and Avis N.E. Surgical menopause: effects on psychological well-being and sexuality. Menopause 14 (2007) 586-591
37. Nicolosi A., Laumann E.O., Glasser D.B., Moreira Jr. E.D., Paik A., Gingell C., and Global Study of Sexual Attitudes and Behaviors Investigators' Group. Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors. Urology 64 (2004) 991-997
38. Laumann E.O., Paik A., Glasser D.B., Kang J.-H., Wang T., Levinson B., et al. A cross-national study of subjective sexual well-being among older women and men: finding from the Global Study of Sexual Attitudes and Behaviors. Arch Sex Behav 35 (2006) 145-161
39. Fears T.R., Ziegler R.G., Donaldson J.L., Falk R.T., Hoover R.N., Stanczyk F.Z., et al. Reproducibility studies and interlaboratory concordance for androgen assays in female plasma. Cancer Epid Biomarkers Prev 9 (2000) 403-412
40. Gruschke A., and Kuhl H. Validity of radioimmunological methods for determining free testosterone in serum. Fertil Steril 76 (2001) 576-582
41. Sinha-Hikim I., Arver S., Beall G., Shen R., Guerrero M., Sattler F., et al. The use of a sensitive equilibrium dialysis method for the measurement of free testosterone levels in healthy, cycling women and human immunodeficiency virus-infected women. J Clin Endocrin Metab 83 (1998) 1312-1318
42. Guay A., Munarriz R., Jacobson J., Talakoub L., Traish A., Quirk F., et al. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res 16 (2004) 112-120
43. Davison S., Bell R., Donath S., Montalto J., and Davis S. Androgen levels in adult females: changes with age, menopause and oophorectomy. J Clin Endocrinol Metab 90 (2005) 3847-3853
44. Burger H.G., Dudley E.C., Cui J., Dennerstein L., and Hopper J.L. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. J Clin Endocrin Metab 85 (2000) 2832-2838
45. Labrie F., Belanger A., Belanger P., Bérubé R., Martel C., Cusan L., et al. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol 99 (2006) 182-188
46. Feldman H.A., Longcope C., Derby C.A., Johannes C.B., Araujo A.B., Coviello A.D., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 87 (2002) 587-598
47. Sowers M.F., Beebe J.L., McConnell J.R., and Jannausch M. Testosterone concentrations in women aged 25-50 years: associations with lifestyle, body composition, and ovarian status. Am J Epidemiol 153 (2001) 256-264
48. Tufano A., Marzo P., Enrini R., Morricone L., Caviezel F., and Ambrosi B. Anthropometric, hormonal and biochemical differences in lean and obese women before and after menopause. J Endocrin Invest 27 (2004) 648-653
49. McTiernan A., Wu L., Chen C., Chlebowski R., Mossavar-Rahmani Y., Modugno F., et al. Relation of BMI and physical activity to sex hormones in postmenopausal women. Obesity 14 (2006) 1662-1677
50. McTiernan A., Tworoger S.S., Rajan K.B., Yasui Y., Sorenson B., Ulrich C.M., et al. Effect of exercise on serum androgens in postmenopausal women: a 12-month randomized clinical trial. Cancer Epidemiol Biomarkers Prev 13 (2004) 1099-1105
51. Braunstein G.D., Sundwall D.A., Katz M., Shifren J.L., Buster J.E., Simon J.A., et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women. Arch Intern Med 165 (2005) 1582-1589
52. Shifren J.L., Braunstein G.D., Simon J.A., Casson P.R., Buster J.E., Redmond G.P., et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343 (2000) 682-688
53. Buster J.E., Kingsberg S.A., Aguirre O., Brown C., Breaux J.G., Buch A., et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 105 (2005) 944-952
54. Shifren J.L., Davis S.R., Moreau M., Waldbaum A., Bouchard C., Derogatis L., et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 13 (2006) 770-779
55. Davis S.R., van der Mooren M.J., van Lunsen R.H., Lopes P., Ribot J., Rees M., et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Menopause 13 (2006) 387-396
56. Bancroft J. Androgens and sexual function in men and women. In: Bagatell C., and Bremner W.J. (Eds). Contemporary endocrinology: androgens in health and disease (2003), Humana Press, Totowa, NJ 259-290
57. Gaudiano B.A., and Herbert J.D. Methodological issues in clinical trials of antidepressant medications: perspectives from psychotherapy outcome research. Psychother Psychosom 74 (2005) 17-25
58. Bausell R.B., Lao L., Bergman S., Lee W.L., and Berman B.M. Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials. Eval Health Prof 28 (2005) 9-26
59. Ganz P.A., Desmond K.A., Leedham B., Rowland J.H., Meyerowitz B.E., and Belin T.R. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 94 (2002) 39-49
60. Andersen B.L., Anderson B., and deProsse C. Controlled prospective longitudinal study of women with cancer: I. sexual functioning outcomes. J Consult Clin Psychol 57 (1989) 683-691
61. Hendren S.K., O'Connor B.L., Liu M., Asano T., Cohen Z., Swallow C.H., et al. Prevalence of male and female sexual dysfunction is high following surgery for rectal cancer. Ann Surg 242 (2005) 212-223
62. Syrjala K.L., Schroeder T.C., Abrams J.R., Atkins T.Z., Brown W.S., Sanders J.E., et al. Sexual function measurement and outcomes in cancer survivors and matched controls. J Sex Res 37 (2000) 213-225
63. Kaplan H.S. A neglected issue: the sexual side effects of current treatments for breast cancer. J Sex Marital Ther 18 (1992) 3-19
64. Kaplan H.S., and Owett T. The female androgen deficiency syndrome. J Sex Marital Ther 19 (1993) 3-24
65. Greendale G.A., Peterson L., Zibecchi L., and Ganz P.A. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 8 (2001) 111-119
66. Speer J.J., Hillenberg B., Sugrue D.P., Blacker C., Kresge C.L., Decker V.B., et al. Study of sexual functioning determinants in breast cancer survivors. Breast J 11 (2005) 440-447
67. Franco B. Androgens and breast cancer. Int J Gynecol Cancer 16 Suppl 2 (2006) 493
68. Lillie E.O., Bernstein L., and Ursin G. Review: The role of androgens and polymorphisms in the androgen receptor in the epidemiology of breast cancer. Breast Cancer Res 5 (2003) 164-173
69. Moe R.E., and Anderson B.O. Guest editorial. Androgens and androgen receptors: a clinically neglected sector in breast cancer biology. J Surg Oncol 95 (2007) 437-439
70. Key T., Appleby P., Barnes I. and Reeves G. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94 (2002) 606-616
71. Missmer S.A., Eliaasen H., Baribieri R.L., et al. Endogenous estrogen, androgen and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96 (2004) 1856-1865
72. Zeleniuch-Jacquotte A., Shore R.E., Akhmedkhanov A., Afanasyeva Y., Kim M.Y., et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 90 (2004) 153-159
73. Kahan Z., Gardi J., Nyari T., Foldesi I., Hajnal-Papp R., Ormandi K., et al. Elevated levels of circulating insulin-like growth factor-1, IGF-binding globulin-3 and testosterone predict hormone-dependent breast cancer in postmenopausal women: a case control study. Int J Oncol 29 (2006) 193-200
74. Micheli A., Muti P., Secreto G., Krogh V., Meneghini E., Venturelli E., et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 112 (2004) 312-318
75. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97 (2005) 755-765
76. Eliassen A.H., Missmer S.A., Tworoger S.S., Spiegelman D., Barbieri R.L., Dowsett M., et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98 (2006) 1406-1415
77. Berrino F., Pasanisi P., Bellati C., Venturelli E., Krogh V., Mastroianni A., et al. Serum testosterone levels and breast cancer recurrence. Int J Cancer 113 (2005) 499-502
78. Col N.F., Kim J.A., and Chlebowski R.T. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res 7 (2005) R535-R540
79. Colditz G.A. Menopausal hormone therapy after breast cancer. Breast Cancer Res 7 (2005) 168-170
80. Dimitrakakis C., Jones R.A., Liu A., and Bondy C.A. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 11 (2004) 531-535
81. Stahlberg C., Pedersen A.T., Lynge E., Andersen Z.J., Keiding N., Hundrup Y.A., et al. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109 (2004) 721-727
82. Tibolone: cancers of the breast and endometrium. Prescrire Int 15 (2006) 107
83. Tworoger S.S., Missmer S.A., Barbieri R.L., Willett W.C., Colditz G.A., and Hankinson S.E. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst 97 (2005) 595-602
84. Tamimi R.M., Hankinson S.E., Chen W.Y., Rosner B., and Colditz G.A. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166 (2006) 1483-1489
85. American Cancer Society. Cancer facts and figures, 2005 (2005), American Cancer Society, Atlanta 14
86. Horwich A., and Swerdlow A.J. Second primary breast cancer after Hodgkin's disease. Br J Cancer 90 (2004) 294-298
87. Kenney L.B., Yasui Y., Inskip P.D., Hammond S., Neglia J.P., Mertens A.C., et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Intern Med 141 (2004) 590-597
88. Rebbeck T.R., Friebel T., Wagner T., Lynch H.T., Garber J.E., Daly M.B., et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in brca1 and brca2 mutation carriers: the PROSE Study Group. J Clin Oncol 23 (2005) 7804-7810
89. Hartmann U., Heiser K., Ruffer-Hesse C., and Kloth G. Female sexual desire disorders: subtypes, classification, personality factors and new directions for treatment. World J Urol 20 (2002) 79-88
90. North American Menopause Society. The role of testosterone therapy in postmenopausal women: position statement of the North American Menopause Society. Menopause 12 (2005) 496-511